2015
The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity
Tubman VN, Mejia P, Shmukler BE, Bei AK, Alper SL, Mitchell JR, Brugnara C, Duraisingh MT. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrobial Agents And Chemotherapy 2015, 60: 613-616. PMID: 26459896, PMCID: PMC4704178, DOI: 10.1128/aac.01668-15.Peer-Reviewed Original ResearchConceptsGardos channel inhibitorChannel inhibitorsSickle cell diseaseC57BL/6 miceClinical trialsCell diseaseAntimalarial developmentPlasmodium growthErythrocyte dehydrationGardos channelSenicapocBlood stagesBiochemical profileAntimalarial activityPrimate plasmodiaVitro growthInhibitorsPatientsParasitemiaBlockadeDiseaseMiceTrials
2009
Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection
Chessler AD, Unnikrishnan M, Bei AK, Daily JP, Burleigh BA. Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection. The Journal Of Immunology 2009, 182: 2288-2296. PMID: 19201883, DOI: 10.4049/jimmunol.0800621.Peer-Reviewed Original ResearchConceptsInfection of miceIFN responseT. cruzi-infected miceIFN-gamma-deficient miceIFN-gamma-producing cellsLevels of IFNEarly type IType I IFN receptorInnate immune responseIntradermal infection modelEarly host responseSite of infectionType I IFNT. cruziI IFN receptorLocal infection siteSite of inoculationType IIntradermal infectionImmune responseI IFNPrimary siteHost responseIFN receptorInfection